课题基金 / 基金详情

STIMULUS-RESPONSE COUPLING IN UREMIC PLATELETS

STIMULUS-RESPONSE COUPLING IN UREMIC PLATELETS
尿毒症血小板的刺激反应耦合
批准号:
3353249
负责人:
THOMAS MACIAG
金额:
$10.51万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1986
资助国家:
美国
项目状态:
已结题
起止时间:
1986-09-30 至 1988-09-29

项目摘要

项目成果

THOMAS MACIAG的其他基金

相似基金

相关文献

中文摘要
翻译
肾病患者的止血功能可能严重受损 疾病。我假设尿毒症的出血性疾病 患者是血小板功能障碍的结果,尤其是在 与涉及血小板糖蛋白Ib(GPIB)的反应有关。一直以来都是 接受GPIB是与von的血小板结合的主要部位 Willebrand因子(VWF)和我们最近确定的GPIB是 凝血酶激活血小板的受体。 为了验证这一假设,将进行以下研究:1) 尿毒症患者血小板表面GPIB结构完整性的检测 患者关于电泳迁移率和由 血小板钙依赖蛋白水解酶和白细胞弹性蛋白酶。这些研究 将决定GPIB中是否存在初级结构异常 尿毒症患者由于已知的蛋白水解酶或糖苷酶的作用 存在于尿毒症血浆或低分子分子中 可与GPIB共价结合。2)研究尿毒症患者的血浆功能 导致正常血小板出现类似缺陷的成分,特别是在 凝血酶和vWF的结合和激活。3)如果这些 尿毒症血小板的过程已经被破坏,实验将被 进行尿毒症血浆蛋白水解酶、糖苷酶或其他 导致这些变化的组件。4)研究企业与企业的相互作用 凝血酶与尿毒症血小板的关系 止血效果是由于结合gpib本身的缺陷造成的。 或在刺激血小板时受体远端的缺陷 回应。凝血酶与尿毒症血小板结合的能力 诱导的血小板活化将通过聚集、5-羟色胺来衡量 纤维蛋白原受体的释放和表达与正常对照 血小板。5)研究正常vWF与尿毒症血小板的相互作用 并确定尿毒症vWF的结构和功能完整性。因此, 尿毒症患者血小板对vWF的反应能力 尿毒症vWF对正常血小板的反应将是 已经确定了。复合缺陷可能产生的协同效应 将检测尿毒症GPIB和尿毒症vWF。
英文摘要
Hemostatic function may be severely compromised in patients with renal disease. It is my hypothesis that the bleeding disorders of uremic patients are the result of platelet dysfunction, particularly with regard to reactions involving platelet glycoprotein Ib (GPIb). It has long been accepted that GPIb is a primary site for the binding to platelets of von Willebrand Factor (vWF) and we have recently established that GPIb is the receptor for platelet activation by thrombin. In order to test this hypothesis, studies will be conducted to: 1) Determine the structural integrity of GPIb on platelets from uremic patients with regard to electrophoretic mobility and fragmentation by the platelet Ca++-dependent protease and leukocyte elastase. These studies will determine whether there are primary structural abnormalities in GPIb in uremic platelets due to the effects of proteases or glycosidases known to be present in uremic plasma or of low molecular weight molecules that may bind covalently to GPIb. 2) Study the ability of uremic plasma components to induce similar defects in normal platelets, particularly with regard to the binding of and activation by thrombin and vWF. 3) If these processes have been compromised in uremic platelets, experiments will be conducted to identify the uremic plasma protease, glycosidase or other components which cause these alterations. 4) Study the interaction of thrombin with uremic platelets to ascertain whether their reduced hemostatic effectiveness is a result of a defect in binding to GPIb itself or a defect distal to the receptor in the excitation of the platelet response. The ability of thrombin to bind to uremic platelets and to elicit platelet activation will be measured by aggregation, serotonin release and expression of fibrinogen receptors in comparison to normal platelets. 5) Study the interaction of normal vWF with uremic platelets and determine the structural and functional integrity of uremic vWF. Thus, the capacity of uremic platelets to respond to vWF as well as the ability of uremic vWF to induce a response in normal platelets will be ascertained. The possible synergistic effect of combined defects in the uremic GPIb and uremic vWF will be examined.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Radiation inactivation experiments predict that a large aggregate form of the insulin receptor is a highly active tyrosine-specific protein kinase.
辐射灭活实验预测,胰岛素受体的大聚集形式是一种高活性的酪氨酸特异性蛋白激酶。
DOI: 10.1021/bi00437a008
发表时间: 1989
期刊: Biochemistry
影响因子: 2.9
作者: [Fujita-Yamaguchi,Y, Harmon,JT, Kathuria,S]
通讯作者: Kathuria,S
A monomer-dimer model explains the results of radiation inactivation: binding characteristics of insulin receptor purified from human placenta.
单体-二聚体模型解释了辐射失活的结果:从人胎盘中纯化的胰岛素受体的结合特征。
DOI: 10.1021/bi00409a020
发表时间: 1988
期刊: Biochemistry
影响因子: 2.9
作者: [Fujita-Yamaguchi,Y, Harmon,JT]
通讯作者: Harmon,JT
CENTER OF BIOMEDICAL RESEARCH EXCELLENCE IN ANGIOGENESIS
  • 批准号:
    6263277
  • 项目类别:
  • 资助金额:
    $189.45万
  • 财政年份:
    2000
  • 负责人:
    THOMAS MACIAG
  • 依托单位:
CENTER OF BIOMEDICAL RESEARCH EXCELLENCE IN ANGIOGENESIS
  • 批准号:
    6394811
  • 项目类别:
  • 资助金额:
    $215.54万
  • 财政年份:
    2000
  • 负责人:
    THOMAS MACIAG
  • 依托单位:
FGF-1 SECRETION PATHWAY
  • 批准号:
    6302371
  • 项目类别:
  • 资助金额:
    $18.72万
  • 财政年份:
    2000
  • 负责人:
    THOMAS MACIAG
  • 依托单位:
CENTER OF BIOMEDICAL RESEARCH EXCELLENCE IN ANGIOGENESIS
  • 批准号:
    6543814
  • 项目类别:
  • 资助金额:
    $13.36万
  • 财政年份:
    2000
  • 负责人:
    THOMAS MACIAG
  • 依托单位:
海外基金